Localization of M 2 and M 3 Muscarinic Receptors in Human Bladder Disorders and Their Clinical Correlations
- 1 July 2006
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 176 (1) , 367-373
- https://doi.org/10.1016/s0022-5347(06)00563-5
Abstract
We studied the cellular localization of muscarinic receptor subtypes 2 and 3 in the human bladder and related any changes in overactive and painful bladder syndromes to measures of clinical dysfunction. Bladder specimens obtained from patients with painful bladder syndrome (11), idiopathic detrusor overactivity (12) and from controls with asymptomatic microscopic hematuria (16) were immunostained using specific antibodies to muscarinic receptor subtypes 2 and 3, and to vimentin, which is a marker for myofibroblasts. Immunostaining results were quantified with computerized image analysis and correlated with clinical dysfunction using frequency and urgency scores. Muscarinic receptor subtype 2 and 3 immunoreactivity was observed in the urothelium, nerve fibers and detrusor layers. In addition, strong myofibroblast-like cell staining, similar to vimentin, was present in the suburothelial region and detrusor muscle. A significant increase in suburothelial myofibroblast-like muscarinic receptor subtype 2 immunoreactivity was seen in patients with painful bladder syndrome (p = 0.0062) and idiopathic detrusor overactivity (p = 0.0002), and in muscarinic receptor subtype 3 immunoreactivity in those with idiopathic detrusor overactivity (p = 0.0122) with a trend in painful bladder syndrome. Muscarinic receptor subtype 2 and 3 immunoreactivity significantly correlated with the urgency score (p = 0.0002 and 0.0206, respectively) and muscarinic receptor subtype 2 immunoreactivity correlated with the frequency score (p = 0.0029). No significant difference was seen in urothelial and detrusor muscarinic receptor subtypes 2 and 3 or vimentin immunostaining. To our knowledge this is the first study to show the cellular localization of muscarinic receptor subtypes 2 and 3 in the human bladder. The increase in muscarinic receptor subtypes 2 and 3 immunostaining in myofibroblast-like cells in clinical bladder syndromes and its correlation with clinical scores suggests a potential role in pathophysiological mechanisms and the therapeutic effect of anti-muscarinic agents.Keywords
This publication has 18 references indexed in Scilit:
- Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT–PCR: changes in ageingBritish Journal of Pharmacology, 2005
- CYSTOMETRIC FINDINGS IN MICE LACKING MUSCARINIC M 2 OR M 3 RECEPTORSJournal of Urology, 2004
- The M2 muscarinic receptor mediates in vitro bladder contractions from patients with neurogenic bladder dysfunctionAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2004
- Muscarinic receptors: What we knowCurrent Urology Reports, 2003
- Research criteria versus clinical criteria for interstitial cystitisInternational Journal of Urology, 2003
- Hypertrophy changes the muscarinic receptor subtype mediating bladder contraction from M3 toward M2American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2003
- The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence SocietyPublished by Elsevier ,2003
- Mice Lacking M2and M3Muscarinic Acetylcholine Receptors Are Devoid of Cholinergic Smooth Muscle Contractions But Still ViableJournal of Neuroscience, 2002
- Increased prevalence of interstitial cystitis: previously unrecognized urologic and gynecologic cases identified using a new symptom questionnaire and intravesical potassium sensitivityUrology, 2002
- Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M 3 subtypeProceedings of the National Academy of Sciences, 2000